Coaxial needle cannula with distal spiral mixer and side ports for fluid injection

Information

  • Patent Grant
  • 10596067
  • Patent Number
    10,596,067
  • Date Filed
    Thursday, October 20, 2016
    8 years ago
  • Date Issued
    Tuesday, March 24, 2020
    4 years ago
Abstract
Disclosed is a multi-lumen mixing device that includes a first and second lumen constructed and arranged to separately pass a first and second reagent to a mixing chamber in the device, where the mixing chamber includes a mixing feature that mixes the first and second reagents. The disclosed multi-lumen mixing device may also include a port in fluid communication with the reaction mixing to permit the product of the combined reagents to be injected into a patent.
Description
BACKGROUND

The present disclosure concerns medical devices that serve to mix two or more components. In particular, it concerns medical devices in which components are passed through separate lumens and then mixed during a procedure for treating a patient.


As further background, there are a variety of medical applications in which two or more flowable components are mixed together for treatment of the patient. As examples, tissue ablation systems have been suggested in which chemicals which react exothermally with each other are mixed and injected into the patient to destroy undesired tissue such as cancerous or precancerous tissue. As additional examples, systems for injection of bone cements have also been suggested wherein two components are mixed just prior to introduction into the patient, whereupon the mixture hardens.


Needs exist for improved or alternative medical devices for achieving admixture of two or more flowable components as a part of a patient treatment regimen. In certain aspects, the present disclosure is addressed to these needs.


SUMMARY

In certain aspects, the present disclosure relates to multi-lumen medical devices that include first and second lumens for passage of first and second reagent materials, respectively. The devices also include a mixing chamber in fluid communication with the first and second lumens, and a mixing element in the chamber that mixes the first and second reagent materials during flow.


Additional aspects of the disclosure as well as features and advantages thereof will be apparent from the further descriptions herein.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 is a perspective view of a multiple reagent injection system including a partial sectional view of a multi-lumen mixing device.



FIG. 2 is an in sectional view of the multi-lumen mixing device of FIG. 1 along lines 2-2.



FIG. 3 is a perspective view of an embodiment of the FIG. 1 multiple reagent injection system including a multi-lumen mixing device.



FIG. 4 is an exploded view of the multiple lumen mixing device of FIG. 3.



FIG. 5 is a partial view of the distal portion of multi-lumen mixing device of FIG. 4.



FIG. 6 illustrates a multiple reagent injection system configured as a thermal chemical ablation system including an ultrasonic imaging system.



FIG. 7 is a partial cross sectional view of a flexible multi-lumen mixing device filling an arterial aneurism.



FIG. 8a is a partial cross sectional view of a multi-lumen mixing device inserted in a collapsed vertebrae.



FIG. 8b illustrates the collapsed vertebrae of FIG. 8a repaired with a bone cement injected from the multi-lumen mixing device.



FIG. 9 is a cross sectional elevational view of an alternative embodiment of a multi-lumen mixing device.



FIG. 10 is a cross sectional view of the FIG. 9 multi-lumen mixing device taken along section line 10-10.



FIG. 11 is a partial cross sectional view of an alternative embodiment of a multi-lumen mixing device.



FIG. 12 is a cross sectional view of the FIG. 11 multi-lumen mixing device taken along section line 12-12.





DETAILED DESCRIPTION

Reference will now be made to certain embodiments and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of this disclosure and the claims is thereby intended, such alterations, further modifications and further applications of the principles described herein being contemplated as would normally occur to one skilled in the art to which this disclosure relates. In several figures, where there are the same or similar elements, those elements are designated with the same or similar reference numerals.


Referring now to FIGS. 1 and 2, multiple reagent injection system 100 is illustrated including infusion system 108 and multi-lumen mixing device 130. Infusion system 108 generally includes infusion devices 110 and 120, including reservoirs 112 and 122 containing reagents 114 and 124 and actuators 116 and 126. Actuators 116 and 126 are linked together by coupling 118. Multiple reagent injection system 100 is used to mix and inject reagents 114 and 124 into a human patient. Several non-limiting examples of embodiments of multiple reagent injection system 100 in use to treat specific conditions are disclosed herein.


Multi-lumen mixing device 130 generally includes an elongate element 140, for example a needle or catheter, defining first lumen 142 and cannula 150 defining lumen 152. The proximal end of multi-lumen mixing device 130 includes hub 132 generally including coupling 134, cannula support 136 and coupling 133. Coupling 134 provides access to first lumen 142. Cannula support 136 supports and secures cannula 150 within elongate element 140 in a coaxial arrangement. Coupling 133 provides access to second lumen 152. Tube 138 couples reservoir 112 to second lumen 152 through coupling 133 while tube 139 couples reservoir 122 to first lumen 142 through coupling 134.


The distal portion of multi-lumen mixing device 130 defines reaction or mixing chamber 160 which generally includes mixing feature 162, third reservoir 149 and needle side ports 146 and 147. In the illustrated embodiment, mixing feature 162 is a spiral mixer that optionally includes notches 164 and/or aperture(s) 166. In certain embodiments, such spiral mixer can be formed as a generally planar structure that has a twisted pattern in its longitudinal axis providing a longitudinal spiral. Such structures can be formed from flat planar lengths of material that have been subjected to twisting forces or can be machined, molded or otherwise manufactured to originally have a spiral shape. Other embodiments can use mixing feature(s) with other mixer configurations, including, but not limited to, a flow dividing static mixer, an alternating spiral mixer, and a static mixer with overlapping semi-helical baffles. Mixing feature 162 can be attached to or integrally formed with cannula 150 and/or catheter 140 or mixing feature 162 can float in reaction chamber 160. In certain embodiments in which mixing feature 162 is integrally formed with cannula 150, an original length of cannulated material can be flattened to a generally planar condition along an end segment thereof. The flattening can block or close the lumen(s) of the cannulated material, either alone or potentially in combination with a substance introduced into the lumen(s) of all or part of the segment which has been, or is to be, flattened. Suitable substances of these purposes can include adhesives, glues, polymerizable material, solders or other bonding agents. Thermal or other welding or fusion of the opposed walls of the flattened segment can also be used to facilitate closure of the lumen(s) of the flattened segment and/or to assist in imparting a permanent predictable shape to the spiral mixer. In instances in which the mixing feature 162, is integrally formed with cannula 150, an outer wall of cannula 150 that is integral with the outer wall of mixing feature 162 can be provided.


Mixing feature 162 can be configured to be rotationally constrained with respect to elongate element 140 or mixing feature 162 can be configured to rotate with respect to elongate element 140. In embodiments where mixing feature 162 can rotate with respect to elongate element 140, such rotation can be driven by the flow of reagents 114 and 124 and/or mixing feature 162 can be coupled to an external power source, for example, by rotating cannula 150 (e.g., an embodiment of FIG. 4 described below).


At the distal end of multi-lumen mixing device 130 is tip 144. Third reservoir 149 is defined by the lumen between the distal end of mixing feature 162 and tip 144. Needle side ports 146 and 147 provide access from reaction chamber 160 to the area outside of multi-lumen mixing device 130 in the patient being treated. Cannula side ports 155 and 156 provide access between second lumen 152 and first lumen 142 and is the location where reagents 114 and 124 first communicate before passing through mixing feature 162. The distal end of second lumen 152 is blocked by occlusion 154 thereby forcing reagent 114 to intermix with reagent 124.


Infusion system 108 provides for simultaneous delivery of reagents 114 and 124 to the patient from reservoirs 112 and 122 through movement of coupling 118 and thereby actuators 116 and 126. As reagents 114 and 124 are expelled from reservoirs 112 and 122, reagent 114 passes through tube 138 to second lumen 152 while reagent 124 passes through tube 139 to first lumen 142. Reagent 114 then is expelled from second lumen 152 through cannula side ports 155 and/or 156 to co-mingle with reagent 124 in first lumen 142. As reagents 114 and 124 proceed distally down multi-lumen mixing device 130 through continued movement of actuators 116 and 126, reagents 114 and 124 enter reaction chamber 160 where mixing feature 162 produces patterns of blending and/or radial mixing to mix reagents 114 and 124 together. In some embodiments, mixing feature 162 may also promote chemical reaction between reagents 114 and 124. After passing through mixing feature 162 mixed reagents 114 and 124 may optionally enter third reservoir 149 that provides an optional delay period before the mixed reagents 114 and 124 are expelled from multi-lumen mixing device 130 through needle side ports 146 and 147. The relative length and diameter of third reservoir 149 can be selected to provide for a delay period by permitting reagent 114 and 124 to chemically react together before being expelled from multi-lumen mixing device 130. In some embodiments, third reservoir 149 may also provide thermal energy storage in the distal portion of multi-lumen mixing device 130. Third reservoir 149 can be optionally omitted by positioning the distal end of mixing feature 162 at or near tip 144 and/or needle side ports 146 and 147.


Tip 144 of multi-lumen mixing device 130 can be configured in several different ways. One embodiment, tip 144 includes a cutting and/or burrowing feature on the distal most end permitting elongate element 140 to be inserted directly into tissue such as skin, organs, arteries, veins and bone. For example, tip 144 may include a beveled cutting edge, a saw-toothed cutting edge, a pointed end, a trocar tip, or any other configuration desired for cutting and/or burrowing into tissue. In other embodiments, tip 144 may be blunted, permitting elongate element 140 to be inserted into an arterial or venous structure and to be advanced therethrough to tissue targeted for treatment. Such an embodiment generally requires a separate introducer as is known in the art for laparoscopic procedures and for venous or arterial access.


In this regard, in various embodiments, elongate element 140, cannula 150 and mixing feature 162 can be constructed of either rigid or flexible materials. In embodiments in which elongate element 140 is configured as a needle with a cutting/burrowing feature on tip 144 to provide direct access to bodily tissue, then elongate element 140 can be made of a rigid material such as a metal or a relatively rigid polymer. In other embodiments where multi-lumen mixing device 130 is configured as a catheter to be introduced through arterial or venous access or into a body cavity through a laparoscopic method, then elongate element 140, mixing feature 162 and cannula 150 may be constructed of a flexible material such as a relatively flexible polymer or flexible metal material. In other embodiments, multi-lumen mixing device 130 includes a cutting/burrowing feature on tip 144 while being constructed of a flexible material. In yet other embodiments, multi-lumen mixing device 130 includes a blunt tip 144 while being constructed of a rigid material. As examples, elongate element 140, cannula 150 and mixing feature 162 can be constructed from metals such as stainless steel (SS) material including, but not limited to 302, 304 or 316 series SS, nitinol (a superelastic nickel-titanium alloy), nickel, cobalt chromium or MP35N, and/or from polymeric materials such as silicone, polyethylene terephthalate, polyurethane, polyamide (e.g. a Nylon), polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, polyethylene (including high molecular weight polyethylene), polytetrafluoroethylene, or polyetheretherketone (PEEK).


In one embodiment, a user may apply a force to coupling 118 to contemporaneously move actuators 116 and 126 to simultaneously deliver reagents 114 and 124 to multi-lumen mixing device 130 through tubes 138 and 139. In other embodiments, a user may selectively activate a computer controlled mechanism that acts upon coupling 118 to move actuators 116 and 126 and yet in other embodiments, reservoirs 112 and 122 may not be physically coupled to one another and actuators 116 and 126 may be separately adjusted to dispense reagents 114 and 124 simultaneously or in selected sequence. For example, individual infusion pumps could replace linked infusion devices 110 and 120 and in yet another embodiment, actuators 116 and 126 could be pulsed relative to one another to provide a different mixing dynamic within multi-lumen mixing device 130.


Multi-lumen mixing device 130 may optionally include visualization marker 148 near tip 144 and/or needle side ports 146 and 147 to provide enhanced visualization during insertion and use. For example, when utilizing ultrasonic visualization techniques, visualization marker 148 could comprise an echogenic marker such as a series of small dimple-like indentations on the outer surface of elongate element 140, for example those used on ECHOTIP® Echogenic Needles available from Cook Medical, Bloomington, Ind., USA, to provide enhanced ultrasonic return. In other embodiments, a radiopaque marker could be used to provide enhanced x-ray response during fluoroscopy or other x-ray visualization techniques. Visualization marker 148 may improve the ability of an interventionalist to monitor the position of tip 144 and/or needle side ports 146 and 147 within a patient's body during use.


Referring now to FIG. 3, an embodiment of system 100 is illustrated including reservoirs 112 and 122 containing reagents 114 and 124, actuators 116 and 126 coupled by coupling 118. Actuators 116 and 126 and reservoirs 112 and 122 are held in injector 128 that is capable of simultaneously moving actuators 116 and 126 by actuating trigger grip 129. Reservoirs 112 and 122 are coupled through tubing 138 and 139 to multi-lumen mixing device 130 through couplings 134 and 133. In the illustrated embodiment, multi-lumen mixing device 130 is comparatively rigid with a needle like catheter 140 including a pencil tip 144 and needle side port 146.


Referring now to FIGS. 4 and 5, the multi-lumen mixing device 130 from FIG. 3 is separately illustrated as elongate element 140 and cannula 150. Elongate element 140 includes, luer fitting 141, tip 144, needle side port 146 and visualization marker 148. In the specific illustrated embodiment, element 140 is a metallic needle and tip 144 is a pencil point. Cannula 150 is formed from a metallic tube in the illustrated embodiment with coupling 133 including a proximal luer fitting with the distal portion of metallic tube 150 forming mixing portion 162 by being crimped and formed into a spiral mixer configuration with cannula side port 155 positioned proximal from the crimping point. In this embodiment, the crimp in the metallic tube forms occlusion 154. In one embodiment, as illustrated in FIG. 2, cannula side ports 155 and 156 are positioned on opposite sides of the crimped metallic tube defining mixing feature 162. Cannula 150 passes through septum 135 on coupling 134. Coupling 134 is constructed and arranged to permit luer fitting 141 on catheter 140 to seal therewith so that cannula 150 passes through the lumen of catheter 140. Coupling 133 attaches to luer fitting 151 on the proximal end of cannula 150. In an alternative embodiment, coupling 133 permits relative rotation between cannula 150 and tube 138 permitting cannula 150 to be rotated with respect to element 140, thereby rotating mixing feature 162 inside element 140.


Referring now to FIG. 6, an embodiment of multiple reagent injection system 100 is illustrated as constructed and arranged for use as a thermochemical ablation device. In general, the illustrated thermochemical ablation device infuses thermochemical ablation reagents that exothermically react when combined. FIG. 6 generally illustrates multi-lumen mixing device 130 inserted into target tissue 50 (e.g., a tumor) under skin 40 of a patient. Needle side ports 146 and 147 are in fluid communication with reservoirs 112 and 122 and ablation reagents 114 and 124 with reaction chamber 160 there between so that combined reagent 115 injects when coupling 118 (and actuators 116 and 126) is moved thereby ablating tissue 52 from target tissue 50. In this embodiment, reagents 114 and 124 are selected to react and generate an exothermic chemical reaction. Such reagents can, for example, be any of those identified herein. Utilized in this way, multiple reagent injection system 100 provides for simultaneous infusion of reagents 114 and 124 as combined reagent 115 into targeted tissue 50 with an exothermic chemical reaction from combined reagent 115 ablating targeted tissue 50. In the illustrated embodiment, reagents 114 and 124 are infused in equal proportions.


In other embodiments where reagents 114 and 124 are infused in different proportions, reservoir 112 may have a different configuration (e.g., different cross-sectional area) than reservoir 122 so that different amounts of fluid are dispensed from reservoir 112 and 122 when actuators 116 and 126 are simultaneously moved (e.g., using coupler 118).


The heat generated from the chemical reaction of combined reagent 115 is sufficient to ablate at least a portion of target tissue 50 surrounding tip 144. Thermochemical ablation reagents 114 and 124 infused into the target tissue 50 can be selected to provide a suitable energy disposition to target tissue 50 and to optionally provide other features such as hyperosmolarity. In some embodiments, reagent 114 may comprise an acid. For example, an acid selected from the group consisting of an acetic acid, peracetic acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, nitrous acid, perchloric acid, phosphoric acid, oxalic acid, pyruvic acid, malonic acid, amino acids (e.g., carboxylic acid derivatives), and the like. Similarly, reagent 124 may comprise a base. For example, a base selected from the group consisting of KOH, NaOH, NH4OH, Ca(OH)2, NaHCO3, K2CO3, BuLi, NaOEt or NaSEt (e.g., Na or K salts of alkoxides or their analogues), NaH, KH, particular amines, and the like.


In some embodiments, the concentration of the base reagent or the acid reagent can be selected so as to fully neutralize the acid and base load applied to the targeted tissue 50 after the thermochemical ablation reaction (e.g. resulting in a mixture having a pH in the range of about 6 to about 8, desirably about 7). In other embodiments, the concentration of the base reagent or the acid reagent can be selected so as to partially neutralize the acid or base load while generating heat energy, thereby providing heated solution with a limited and safe level of remaining acid or base load.


In various embodiments, the particular acid and the particular base may be selected to provide a desired heat generation and low toxicity byproduct. For example, in one embodiment, reagent 114 may be either acetic acid or hydrochloric acid, while reagent 124 may be NaOH, NaOEt or NH4OH. Multiple reagent injection system 100 maintains reagent 114 separate from reagent 124 until reagents 114 and 124 reach reaction chamber 160 and are subsequently infused as combined reagents 115 into target tissue 50 allowing reagents 114 and 124 to chemically react to generate ablation heat energy. Such chemical reaction can begin within the distal portion of multi-lumen mixing device 130 in reaction chamber 160 thereby heating the distal portion of element 140 that may also aid the ablation of target tissue 50. In some embodiments, the byproducts from the chemical reaction of reagents 114 and 124 may further benefit the ablation process, for example, due to hyperosmolarity of combined reagents 115 to target tissue 50.


In yet other embodiments, reagents 114 and 124 may include other reactive substances. For example, reagent 114 may comprise electrophiles, and reagent 124 may comprise nucleophiles. In yet another embodiment, reagent 114 may include electrophiles from the group consisting of acetic anhydride, acetyl chloride, acetyl bromide, other anhydrides, other acid halides and the like while reagent 124 may comprise a nucleophile selected from the group consisting of alkoxides, thio analogues, mercaptans (e.g., sulfhydryl), some amines and the like. Other nucleophiles could include alcohols, sugar molecules, water, and endogenous nucleophiles. In other embodiments, reagent 124 may comprise a nucleophile selected from the group of previously described bases (e.g., NaOH, NaOEt or NH4OH or the like). Thus, some embodiments of multiple reagent injection system 100 can infuse an electrophile (such as acetyl chloride) with a nucleophile (such as NaOH) that chemically react with one another. The byproducts of the chemical reaction provide therapeutically significant heat generation while at least partially neutralizing any acid (or base) load.


In other embodiments, reagents 114 and 124 may include other reactive substances. For example, reagent 114 may comprise a particular oxidizing agent, and reagent 124 may comprise a certain reducing agent. In yet other embodiments, the thermochemical ablation reagents could be selected to have useful imaging or other analyzable features (e.g., fluorescence, nuclear isotopes, MR imaging characteristics, or the like) to permit the evaluation of reagent distribution in target tissue 50 and throughout the body before and after treatment.


In some embodiments, one or both of reagents 114 and/or 124 can be mixed with a denaturing agent that enhances the tissue ablation process. For example, a denaturing agent such as a sclerosant, detergent, urea or sodium perchlorite (or another substance from the Hofmeister series) can be mixed with the reagent 114 or reagent 124 prior to injection through multi-lumen mixing device 130. The denaturing agent may react upon targeted tissue 50 to enhance the ablation effect caused by thermochemical reaction of reagents 114 and 124.


In yet other embodiments, a drug may be added to one or both of the thermochemical reagents 114 and 124 to provide a pharmacological effect on target tissue 50 in addition to any thermochemical ablation effects. For example, a chemotherapy drug can be added to reagent 114 and/or 124 prior to injection through multi-lumen device 130. The chemotherapy drug can then be administered to the target tissue 50 through multi-lumen mixing device 130 to provide the pharmacological effect contemporaneously with the ablation effect from thermochemical reaction from combined reagent 115. In yet another embodiment, multi-lumen mixing device 130 can be modified with an additional lumen that bypasses reaction chamber 160 and provides for simultaneous injection of a drug at or near tip 144, or near needle side ports 146 and 147. In another embodiment, such an additional lumen could allow simultaneous injection into reaction chamber 160 (such as the configuration illustrated in FIGS. 9-10, discussed below).


Still referring to FIG. 6, some embodiments of multiple reagent injection system 100 may include the use of medical imaging system 90 to provide real-time monitoring of multi-lumen mixing device 130 during its insertion and delivery of reagents 114 and 124 as combined reagents 115. For example, as illustrated in FIG. 6, medical imaging system 90 could include an ultrasonic imaging device to enable a user to view the distal portion of multi-lumen mixing device 130 in target tissue 50. Imaging system 90 may include probe 94 such as the illustrated ultrasonic probe. Probe 94 can be manipulated on the outside of a patient's body or within a body cavity to provide imaging of target tissue 50 and/or multi-lumen mixing device 130. Probe 94 may be connected to a display system 92 that interprets the signal from probe 94 and generates a display of the targeted portion of the patient's body. For example, as illustrated in FIG. 6, display system 92 shows distal portion of multi-lumen mixing device 130 as inserted into target tissue 50 for delivery of combined reagent 115. In other embodiments, imaging systems may comprise other types of imaging systems other than ultrasound imaging. For example, imaging system 90 could include a fluoroscope, a CT imaging system or the like. In some embodiments, the outside of catheter 140 may include depth markers that are directly viewable by a user to determine the depth of insertion through skin 40 to indicate the approximate depth of insertion. In addition, such depth markers can be spaced at regular intervals (such as centimeters) for use as a scale to measure the relative size of internal structures (such as tumors, etc.).


Referring now to FIG. 7, an embodiment of a comparatively flexible multi-lumen mixing device 130 is illustrated as constructed and arranged for treating an aneurism in an arterial wall. Illustrated are arteries 60 containing aneurism 62 with element 140 advanced through artery 60 with tip 144 and needle side ports 146 and 147 positioned within aneurism 62. Multi-lumen mixing device 130 has injected combined reagents 115 into aneurism 62. In this embodiment, combined reagents 115 polymerize and/or promote a thrombolytic reaction within aneurism 62 to seal off aneurism 62. As discussed elsewhere, a medical imaging device can be used to assist in the insertion of multi-lumen mixing device 130 into aneurism 62 and the subsequent injection of combined reagent 115 to substantially fill aneurism 62 with the resultant polymer and/or clot. In an alternative embodiment, combined reagent 115 forms a biocompatible polymer that substantially fills aneurism 62.


Referring now to FIGS. 8a and 8b, an embodiment of multi-lumen mixing device 130 is illustrated as constructed and arranged as a system for stabilizing a collapsed vertebrae by introducing a bone cement mixture (in the form of combined reagents 115) into the collapsed vertebrae. FIG. 8a illustrates collapsed vertebrae 70 with a compression fracture. Vertebrae 70 may be, for example, in the thoracic or lower spine of the patient. The compression fracture of vertebrae 70 collapses the bone tissue at the vertebrae body. This condition can be caused by osteoporosis, tumor or trauma to the back.


The illustrated embodiment of multi-lumen mixing device 130 can be utilized for stabilizing collapsed vertebrae 70 by either vertebroplasty or kyphoplasty, both of which are medical procedures for restoring structural integrity to collapsed vertebrae. These procedures stabilize collapsed vertebrae 70 by filling in open spaces within the vertebrae body with bone cement to provide a more continuous and solid form. These procedures may also restore an approximate original shape or height to vertebrae 70. It should be noted that the disclosed device and method applies to both vertebroplasty and kyphoplasty and other procedures for stabilizing and/or repairing damaged bone of patients. While the embodiments discussed herein are specifically describing vertebroplasty, a person of ordinary skill in the art will recognize how these teachings apply to the other related procedures.


These procedures are normally performed using an x-ray medical imaging device such as a fluoroscope to enhance visualization. These procedures can be performed under local anesthesia and/or light sedation. A nick is made in the skin near the spine and element 140 is inserted percutaneously into the open spaces of vertebrae 70 through the left or right pedicle of vertebrae 70 as is known in the art. Tip 144 may be used as a cutting instrument to generate a hole in the skin and access hole 72 into vertebrae 70 or an introducer (not illustrated) can be used to generate access holes so that element 140 can be inserted therethrough.


After insertion, a bone cement mixture in the form of combined reagents 115 can be dispensed from multi-lumen mixing device 130 into vertebrae 70 through needle side ports 146 and 147 to form a solid structure 74 that supports the collapsed vertebrae. The bone cement mixture/combined reagents 115 forms a solid structure 74 by chemically reacting or curing the reagents to become solid. Solid structure 74 may be formed within and/or about the collapsed vertebrae to stabilize vertebrae 70′ and may help restore vertebrae spacing and alleviate nerve pinching by supporting collapsed vertebrae 70 at least in a compressive mode. Solid structure 74 can substantially fill the open space of the collapsed vertebrae 70 to provide a more dense and continuous vertebrae 70′ which can, in some cases, enhance mobility and alleviate pain in the patient.


In one example, the first reagent of combined reagents 115 includes methylmethacrylate, sodium phosphate, or a mixture thereof and the second reagent of combined reagents 115 includes polymethylmethacrylate, monocalcium phosphate, tricalcium phosphate, calcium carbonate or a mixture thereof. The first reagent may also include a radio pacifier or radiopaque material such as derivatives of tungsten, barium, bismuth, etc.


Referring now to FIGS. 9-10, an alternate embodiment of multi-lumen mixing device 130 is illustrated as multi-lumen mixing device 230 which generally includes cannulated element 240 defining lumen 242 and element 250 defining lumens 252 and 253. The distal portion of multi-lumen mixing device 230 defines reaction chamber 260 which generally includes mixing feature 262, reservoir 249 and ports 246 and 247. In the illustrated embodiment, mixing feature 262 is a spiral mixer as discussed above. Other various embodiments can use other mixing features with other mixer configurations including those disclosed above with regard to mixer 162. Mixing feature 262 can be attached to or integrally formed with element 250 and/or element 240 or alternatively mixing feature 262 can float in reaction chamber 260.


The distal end of multi-lumen mixing device 230 is tip 244, reservoir 249 is defined by the lumen between the distal end of mixing feature 262 and tip 244, ports 246 and 247 provide access from reaction chamber 260 to the area outside of multi-lumen mixing device 230. Ports 255 and 256 provide access between lumen 252 and lumen 242 while ports 257 and 258 provide access between lumen 253 and 242. The distal end of lumens 252 and 253 are blocked by occlusion 254 thereby forcing the reagents passing through lumens 252 and 253 to intermix with the reagent passing through lumen 242.


While not illustrated, the multi-lumen mixing device 230 illustrated in FIGS. 9-10 can be connected to an infusion system containing three separate reagents so that tube 237 connects the first reagent to lumen 252, tube 238 connects the second reagent to lumen 253 while tube 239 connects a third reagent to lumen 242. Any known method, including those discussed above with regard to infusion system 108, can be utilized to infuse the three reagents through multi-lumen mixing device 230 to eject a combined reagent from ports 246 and 247.


Referring now to FIGS. 11 and 12, yet another embodiment of a multi-lumen mixing device is illustrated as multi-lumen mixing device 330 that generally includes cannulated element 340 defining lumens 342 and 343. Lumens 342 and 343 merge at junction 345 into a single lumen defining reaction chamber 360 at the distal portion of multi-lumen mixing device 330. Reaction chamber 360 includes mixing feature 362 and ends at port 346 and tip 344. In the illustrated embodiment, mixing feature 362 is a spiral mixer that floats in reaction chamber 360. In other embodiments, mixing feature 362 may be incorporated with or attached to element 340.


In one embodiment, element 340 may be constructed from a standard side-by-side lumen catheter with one lumen collapsed and welded against the other to form the illustrated structure. In yet other embodiments, element 140 can be molded or formed as the illustrated configuration.


While the disclosure has been illustrated and described in detail in the drawings and foregoing description, the same is to be considered as illustrative and not restrictive in character, it being understood that only the preferred embodiments have been shown and described and that all changes and modifications that come within the spirit of the disclosure are desired to be protected.

Claims
  • 1. A mixing injection device for use with a patient, the device comprising; a needle having a tissue penetrating tip on a distal end and a first hub on a proximal end, the needle defining a first lumen fluidly coupling a needle side port to the first hub, wherein the first lumen is adapted to pass a first reagent between the first hub and the needle side port, wherein the needle is constructed from a rigid material having sufficient rigidity to open a path through tissue and wherein a distal end of the first lumen is either closed or substantially narrowed; a cannula defining a second lumen, the cannula including a second hub and a cannula side port, wherein the second lumen is adapted to pass a second reagent between the second hub and the cannula side port, wherein the cannula is co-axially positioned inside the first lumen, wherein the second lumen terminates into the first lumen, and wherein the second lumen is occluded distally from the cannula side port;a mixing element on the cannula positioned distally from the cannula side port and inside the first lumen, wherein the second reagent mixes with the first reagent after passing through the cannula side port into the first lumen and traversing along the mixing element, wherein the mixing element is located distally from where the second lumen terminates into the first lumen, and wherein the mixed first and second reagents are injected into the patient through the needle side port.
  • 2. The mixing injection device of claim 1, wherein the mixing element and the cannula are unitarily composed of a single piece.
  • 3. The mixing injection device of claim 1, wherein the mixing element is shaped from a distal portion of the cannula.
  • 4. The mixing injection device of claim 1, wherein a distal end of the cannula is substantially flattened to a generally planar condition along a longitudinal axis of the cannula and is twisted along the longitudinal axis of the cannula.
  • 5. The mixing injection device of claim 1, wherein the tissue penetrating needle tip is selected from the group comprising: a beveled cutting edge tip, a saw-toothed cutting edge tip, a pointed end tip, a trocar tip, and a pencil point tip.
  • 6. The mixing injection device of claim 1, wherein the needle is constructed of a metal.
  • 7. The mixing injection device of claim 1, wherein the cannula passes through the first hub and is rotatable relative to the needle and the first hub.
  • 8. A method of mixing a first and second reagent using the claim 1 mixing injection device while injecting the first and second reagent into a target tissue in a patient's body, the method comprising: penetrating the target tissue by cutting or burrowing through the target tissue with the tissue penetrating tip on the needle thereby creating a passage into the target issue;after the needle has penetrated the target tissue and while the needle is in the target tissue, injecting the first reagent through the first lumen of the needle and the second reagent through the second lumen of a cannula that is co-axially positioned inside the first lumen to the cannula side port that passes the second reagent into the first lumen, wherein the first and second reagents traverse along the mixing element positioned inside the first lumen distally from the cannula side port thereby mixing the first and second reagents and forming a combined reagent, wherein the second reagent is fluidly isolated from the first reagent when the second reagent is in the second lumen; andafter the second reagent passes through the cannula side port and is mixed with the first reagent in the first lumen, ejecting the combined reagent out of the needle side port into the target tissue.
  • 9. The method of claim 8, wherein the mixing element is a generally planar structure that has a twisted pattern along its longitudinal axis.
  • 10. The method of claim 8, further comprising ablating tissue by inserting the needle into the target tissue to be ablated, wherein the combined reagent generates an exothermic chemical reaction sufficient to ablate the target tissue.
  • 11. The method of claim 8, further comprising stabilizing a vertebra by inserting the needle into the vertebra, wherein the combined reagent is a bone cement.
  • 12. The method of claim 8, further comprising rotating the cannula relative to the needle while injecting the first and second reagents.
  • 13. A system for mixing reagents during injection into a patient, the system comprising: a first reservoir containing a first reagent;a second reservoir containing a second reagent; andthe mixing injection device of claim 1, wherein the first hub is fluidly coupled to the first reservoir; andwherein the second hub is fluidly coupled to the second reservoir.
  • 14. The system of claim 13, wherein the first lumen defines a third reservoir longitudinally positioned between the mixing element and the cannula side port.
  • 15. The system of claim 13, wherein the mixing element is a generally planar structure that has a twisted pattern along its longitudinal axis.
  • 16. The system of claim 13, wherein the mixing element is shaped from a distal portion of the cannula.
  • 17. The system of claim 13, wherein the cannula passes through the first hub and the cannula is rotatable relative to the first hub and the needle.
  • 18. The system of claim 13, wherein the tissue penetrating tip is selected from a group comprising: a beveled cutting edge tip, a saw-toothed cutting edge tip, a pointed end tip, a trocar tip, and a pencil point tip.
REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 12/914,167 filed Oct. 28, 2010, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/255,886 filed Oct. 29, 2009 which are both hereby incorporated by reference in their entirety.

US Referenced Citations (147)
Number Name Date Kind
203387 Stohlmann et al. May 1878 A
319698 Graefe Jun 1885 A
3373906 De Hart Mar 1968 A
3470869 Fenton Oct 1969 A
3587982 Campbell Jun 1971 A
3738535 Nicholls Jun 1973 A
3774604 Danielsson Nov 1973 A
3815878 Baskas Jun 1974 A
3953002 England, Jr. Apr 1976 A
4040420 Speer Aug 1977 A
4044757 McWhorter Aug 1977 A
4069814 Clemens Jan 1978 A
4265618 Herskovitz May 1981 A
4538920 Drake Sep 1985 A
4631055 Redl Dec 1986 A
4673395 Phillips Jun 1987 A
4689042 Sarnoff Aug 1987 A
4753536 Spehar Jun 1988 A
4795433 Sarnoff Jan 1989 A
4796622 Lu et al. Jan 1989 A
4808184 Tepic Feb 1989 A
4874368 Miller Oct 1989 A
4978336 Capozzi Dec 1990 A
4979518 Itoh et al. Dec 1990 A
5015232 Maglinte May 1991 A
5104375 Wolf Apr 1992 A
5116315 Capozzi May 1992 A
5147323 Haber Sep 1992 A
5174653 Halat Dec 1992 A
5188602 Nichols Feb 1993 A
5199949 Haber Apr 1993 A
5211627 William May 1993 A
5240146 Smedley Aug 1993 A
5271527 Haber Dec 1993 A
5298023 Haber Mar 1994 A
5306237 Clement Apr 1994 A
5314412 Rex May 1994 A
5443454 Tanabe Aug 1995 A
5445614 Haber Aug 1995 A
5472422 Ljungquist Dec 1995 A
5474540 Miller Dec 1995 A
5478323 Westwood Dec 1995 A
5505704 Pawelka Apr 1996 A
5575409 Gruendeman Nov 1996 A
5685846 Michaels, Jr. Nov 1997 A
5725498 Janzen Mar 1998 A
5749968 Melanson May 1998 A
5814022 Antanavich Sep 1998 A
5865818 Gould Feb 1999 A
5935437 Whitmore Aug 1999 A
6033401 Edwards Mar 2000 A
6053899 Slanda Apr 2000 A
6190380 Abela Feb 2001 B1
6224591 Claren et al. May 2001 B1
6371975 Cruise Apr 2002 B2
6379378 Werneth et al. Apr 2002 B1
6454739 Chang Sep 2002 B1
6471670 Enrenfels Oct 2002 B1
6576001 Werneth et al. Jun 2003 B2
6599008 Heusser Jul 2003 B2
6620125 Redl Sep 2003 B1
6629774 Gruendeman Oct 2003 B1
6629947 Sahatjian Oct 2003 B1
6648852 Wirt Nov 2003 B2
6699214 Gellman Mar 2004 B2
6796966 Thomas Sep 2004 B2
6824555 Towler et al. Nov 2004 B1
6832995 Towler et al. Dec 2004 B1
6905510 Saab Jun 2005 B2
6972005 Boehm, Jr. Dec 2005 B2
6994686 Cruise Feb 2006 B2
7037289 Dodge May 2006 B2
7097642 Sprague et al. Aug 2006 B1
7118591 Frank et al. Oct 2006 B2
7211066 Merrill May 2007 B1
7270654 Griego Sep 2007 B2
7485107 DiFiore et al. Feb 2009 B2
7490738 Crews Feb 2009 B2
7572257 Whayne et al. Aug 2009 B2
7575131 Feinberg Aug 2009 B2
7811291 Liu Oct 2010 B2
7850656 McKay Dec 2010 B2
7914484 Yokoyama Mar 2011 B2
7955301 McKay Jun 2011 B1
7985020 Pappalardo Jul 2011 B2
8047407 Wheeler Nov 2011 B2
8221452 Edwards Jul 2012 B2
8308681 Slocum Nov 2012 B2
8460235 Keller Jun 2013 B2
9155874 Miyazaki Oct 2015 B2
20010047187 Milo Nov 2001 A1
20020016621 Werneth et al. Feb 2002 A1
20020049409 Noda et al. Apr 2002 A1
20020049484 Werneth et al. Apr 2002 A1
20030048694 Horner Mar 2003 A1
20030055454 Zucker Mar 2003 A1
20040005295 Lee et al. Jan 2004 A1
20050085769 MacMahon et al. Apr 2005 A1
20050187542 Auge, II et al. Aug 2005 A1
20060208000 Murray Sep 2006 A1
20060253088 Chow et al. Nov 2006 A1
20070016128 Keller Jan 2007 A1
20070027449 Godara et al. Feb 2007 A1
20070073267 Muller Mar 2007 A1
20070088271 Richards Apr 2007 A1
20070164047 Reidt Jul 2007 A1
20070167776 Kochavi et al. Jul 2007 A1
20070173786 Recinella et al. Jul 2007 A1
20070191781 Richards Aug 2007 A1
20070203479 Auth et al. Aug 2007 A1
20070213686 Mathur Sep 2007 A1
20080045925 Stepovich Feb 2008 A1
20080103564 Burkinshaw May 2008 A1
20080121657 Voegele May 2008 A1
20080125798 Osborne May 2008 A1
20080243112 De Neve Oct 2008 A1
20080260598 Gross Oct 2008 A1
20080262469 Brister Oct 2008 A1
20090099547 Radmer Apr 2009 A1
20090122638 Sato May 2009 A1
20090124986 Hayakawa May 2009 A1
20090131864 Pickhard May 2009 A1
20090149746 Chernomorsky Jun 2009 A1
20090170933 Leckrone Jul 2009 A1
20090198217 Thorne, Jr. Aug 2009 A1
20090306623 McIntosh Dec 2009 A1
20090318893 English Dec 2009 A1
20100010436 Wang Jan 2010 A1
20100054075 Valaie Mar 2010 A1
20100063440 Kitani Mar 2010 A1
20100145304 Cressman Jun 2010 A1
20100217231 Ilan Aug 2010 A1
20100268158 Porter Oct 2010 A1
20110106071 Bosel May 2011 A1
20110128814 Hanada Jun 2011 A1
20110150703 Castro Jun 2011 A1
20110152616 Deal Jun 2011 A1
20110184350 McKay Jul 2011 A1
20110245803 Barker, Jr. Oct 2011 A1
20110251546 Sullivan Oct 2011 A1
20110275988 Davis Nov 2011 A1
20110276031 Hoang Nov 2011 A1
20110288531 Chang Nov 2011 A1
20110295212 Greter Dec 2011 A1
20110301545 Nalesso Dec 2011 A1
20120029471 Lee Feb 2012 A1
20150065993 Arocha Mar 2015 A1
Foreign Referenced Citations (3)
Number Date Country
WO 8303961 Nov 1983 WO
WO 200168160 Sep 2001 WO
WO 2008106357 Sep 2008 WO
Related Publications (1)
Number Date Country
20170035653 A1 Feb 2017 US
Provisional Applications (1)
Number Date Country
61255886 Oct 2009 US
Continuations (1)
Number Date Country
Parent 12914167 Oct 2010 US
Child 15298312 US